MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cjca.2019.02.016

Медицинская библиотека · The Canadian journal of cardiology · 2019

Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy.

You Hongzhao, Jiang Wenxi, Jiao Meng, Wang Xue, Jia Lixin, You Shijie, Li Yulin, Wen Haichu, Jiang Hongfeng, Yuan Hui, Huang Jie, Qiao Bokang, Yang Ya, Jin Mei, Wang Yuan, Du Jie

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Prognosis in patients with pediatric dilated cardiomyopathy (PDCM) is urgently required to identify high-risk patients. Elevated soluble ST2 (sST2) is associated with prognosis in adult patients with heart failure. This study aimed to assess the prognostic value of sST2 in PDCM.

METHODS

Ninety-four patients with PDCM were enrolled after admission from 2 centres in China and followed up for adverse events (death, cardiac transplantation, and heart-failure-related rehospitalization). B-type natriuretic peptide (BNP) and sST2 levels were measured.

RESULTS

Over a median of 678 (interquartile range [IQR]: 533-785) days, 28 (29.8%) adverse events occurred. Patients in the highest tertile of sST2 levels had increased risk of short-term (< 6 months) (adjusted hazard ratio [HR]: 8.36, 95% confidence interval [CI], 1.02-73.52; P < 0.05) and long-term adverse events (2 years) (adjusted HR: 4.23; 95% CI, 1.32-13.60; P < 0.01) than those in lower tertiles. The C-statistic was increased with addition of sST2 to BNP from 0.697 (95% CI, 0.541-0.852) to 0.812 (95% CI, 0.697-0.939) for short-term and from 0.712 (95% CI, 0.604-0.819) to 0.798 (95% CI, 0.697-0.899) for prediction of long-term adverse events. An intermediate-risk subgroup was identified, and 24% had adverse events. When serial measurements were taken in a nested case-control subgroup, sST2 levels were constantly high in patients with late adverse events (> 6 months) but gradually decreased in nonadverse-event controls compared with 3-month and 6-month baseline levels.

CONCLUSIONS

In patients with PDCM, serum sST2 levels are associated with adverse events and have robust prognostic value. Serial measurements of sST2 could help in managing patients for monitoring outcomes of treatment.

Для цитирования: You Hongzhao, Jiang Wenxi, Jiao Meng, Wang Xue, Jia Lixin, You Shijie, Li Yulin, Wen Haichu, Jiang Hongfeng, Yuan Hui, Huang Jie, Qiao Bokang, Yang Ya, Jin Mei, Wang Yuan, Du Jie. Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy.. The Canadian journal of cardiology. 2019. DOI: 10.1016/j.cjca.2019.02.016.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.